Corcept Therapeutics Inc (CORT) stock
CORTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 11/30349% above fair value
$72.94−0.77 (-1.04%)
Close on Nov 13, 2026Market cap $7.88BP/E 173.7Yield –
Corcept Therapeutics cash
Cash and short-term investments held at the end of each period.
Corcept Therapeutics's cash was $308.20M at Jun 30, 2026. For fiscal 2025 it was $372.15M, down 3.2% from the year before. Over ten years it grew 24.9% a year on average. The highest annual figure on record is $440.70M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $372.15M | -3.2% |
| FY2024 | Dec 31, 2024 | $384.33M | +4.4% |
| FY2023 | Dec 31, 2023 | $368.22M | -14.7% |
| FY2022 | Dec 31, 2022 | $431.67M | +93.1% |
| FY2021 | Dec 31, 2021 | $223.54M | -49.3% |
| FY2020 | Dec 31, 2020 | $440.70M | +59.7% |
| FY2019 | Dec 31, 2019 | $275.96M | +33.5% |
| FY2018 | Dec 31, 2018 | $206.76M | +133.0% |
| FY2017 | Dec 31, 2017 | $88.74M | +72.2% |
| FY2016 | Dec 31, 2016 | $51.54M | +27.5% |
| FY2015 | Dec 31, 2015 | $40.44M | +66.8% |
| FY2014 | Dec 31, 2014 | $24.25M | -55.8% |
| FY2013 | Dec 31, 2013 | $54.88M | -41.0% |
| FY2012 | Dec 31, 2012 | $93.03M | +134.7% |
| FY2011 | Dec 31, 2011 | $39.64M | +61.3% |
| FY2010 | Dec 31, 2010 | $24.58M | +3.0% |
| FY2009 | Dec 31, 2009 | $23.87M | +62.2% |
| FY2008 | Dec 31, 2008 | $14.72M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $308.20M | -9.9% |
| Q1 FY2026 | Mar 31, 2026 | $338.18M | +4.8% |
| Q4 FY2025 | Dec 31, 2025 | $372.15M | -3.2% |
| Q3 FY2025 | Sep 30, 2025 | $421.68M | +10.9% |
| Q2 FY2025 | Jun 30, 2025 | $342.23M | -27.7% |
| Q1 FY2025 | Mar 31, 2025 | $322.76M | -21.4% |
| Q4 FY2024 | Dec 31, 2024 | $384.33M | +4.4% |
| Q3 FY2024 | Sep 30, 2024 | $380.34M | +7.1% |
| Q2 FY2024 | Jun 30, 2024 | $473.16M | +30.3% |
| Q1 FY2024 | Mar 31, 2024 | $410.76M | -11.7% |
| Q4 FY2023 | Dec 31, 2023 | $368.22M | -14.7% |
| Q3 FY2023 | Sep 30, 2023 | $355.23M | -10.4% |
| Q2 FY2023 | Jun 30, 2023 | $363.26M | -1.8% |
| Q1 FY2023 | Mar 31, 2023 | $465.06M | +34.6% |
| Q4 FY2022 | Dec 31, 2022 | $431.67M | +93.1% |
| Q3 FY2022 | Sep 30, 2022 | $396.26M | +9.7% |
| Q2 FY2022 | Jun 30, 2022 | $370.09M | +0.0% |
| Q1 FY2022 | Mar 31, 2022 | $345.53M | -7.4% |
| Q4 FY2021 | Dec 31, 2021 | $223.54M | -49.3% |
| Q3 FY2021 | Sep 30, 2021 | $361.33M | -15.7% |
| Q2 FY2021 | Jun 30, 2021 | $369.98M | -8.7% |
| Q1 FY2021 | Mar 31, 2021 | $372.96M | +21.4% |
| Q4 FY2020 | Dec 31, 2020 | $440.70M | +59.7% |
| Q3 FY2020 | Sep 30, 2020 | $428.79M | +85.1% |
| Q2 FY2020 | Jun 30, 2020 | $405.36M | +101.1% |
| Q1 FY2020 | Mar 31, 2020 | $307.32M | +64.4% |
| Q4 FY2019 | Dec 31, 2019 | $275.96M | +33.5% |
| Q3 FY2019 | Sep 30, 2019 | $231.65M | +18.7% |
| Q2 FY2019 | Jun 30, 2019 | $201.54M | +26.0% |
| Q1 FY2019 | Mar 31, 2019 | $186.91M | +49.1% |
| Q4 FY2018 | Dec 31, 2018 | $206.76M | +133.0% |
| Q3 FY2018 | Sep 30, 2018 | $195.19M | +159.7% |
| Q2 FY2018 | Jun 30, 2018 | $159.95M | +141.7% |
| Q1 FY2018 | Mar 31, 2018 | $125.36M | +137.5% |
| Q4 FY2017 | Dec 31, 2017 | $88.74M | +72.2% |
| Q3 FY2017 | Sep 30, 2017 | $75.16M | +57.0% |
| Q2 FY2017 | Jun 30, 2017 | $66.17M | – |
| Q1 FY2017 | Mar 31, 2017 | $52.77M | – |
| Q4 FY2016 | Dec 31, 2016 | $51.54M | – |
| Q3 FY2016 | Sep 30, 2016 | $47.87M | – |
See a number that looks wrong?